O	0	1	A
O	2	13	Prospective
O	14	24	Randomized
O	25	30	Trial
O	31	33	of
O	34	37	the
O	38	46	Efficacy
O	47	49	of
B-intervention	50	56	Fibrin
I-intervention	57	61	Glue
I-intervention	61	62	,
I-intervention	63	76	Triamcinolone
I-intervention	77	86	Acetonide
I-intervention	86	87	,
I-intervention	88	91	and
I-intervention	92	100	Quilting
I-intervention	101	108	Sutures
O	109	111	in
B-condition	112	118	Seroma
O	119	129	Prevention
O	130	135	after
O	136	146	Latissimus
O	147	152	Dorsi
O	153	159	Breast
O	160	174	Reconstruction
O	174	175	.

O	176	181	Donor
O	181	182	-
O	182	186	site
O	187	193	seroma
O	194	196	is
O	197	200	the
O	201	205	most
O	206	212	common
O	213	225	complication
O	226	235	following
O	236	246	latissimus
O	247	252	dorsi
O	253	257	flap
O	258	264	breast
O	265	279	reconstruction
O	279	280	.

O	281	288	Various
O	289	295	agents
O	296	299	and
O	300	310	techniques
O	311	315	have
O	316	325	attempted
O	326	328	to
O	329	337	minimize
O	338	344	seroma
O	345	354	formation
O	354	355	.

O	356	359	The
O	360	367	purpose
O	368	370	of
O	371	375	this
O	376	381	study
O	382	385	was
O	386	388	to
O	389	396	compare
O	397	400	the
O	401	409	efficacy
O	410	412	of
O	413	422	different
O	423	431	products
O	432	435	and
O	436	444	quilting
O	445	452	sutures
O	453	455	at
O	456	462	seroma
O	463	473	prevention
O	473	474	.

O	475	479	This
O	480	482	is
O	483	484	a
O	485	491	single
O	491	492	-
O	492	498	center
O	498	499	,
O	500	506	double
O	506	507	-
O	507	514	blinded
O	514	515	,
O	516	526	randomized
O	526	527	,
O	528	538	controlled
O	539	544	trial
O	545	547	of
O	548	549	a
O	550	561	consecutive
O	562	568	series
O	569	571	of
B-eligibility	572	578	breast
I-eligibility	579	585	cancer
I-eligibility	586	594	patients
O	595	596	(
O	596	597	n
O	598	599	=
B-total-participants	600	602	96
O	602	603	)
B-eligibility	604	614	undergoing
I-eligibility	615	625	latissimus
I-eligibility	626	631	dorsi
I-eligibility	632	636	flap
I-eligibility	637	651	reconstruction
I-eligibility	652	661	performed
I-eligibility	662	664	by
I-eligibility	665	666	a
I-eligibility	667	673	single
I-eligibility	674	681	surgeon
O	681	682	.

O	683	691	Patients
O	692	696	were
O	697	707	randomized
O	708	710	to
O	711	718	receive
O	719	720	(
O	720	721	1
O	721	722	)
O	723	729	fibrin
O	730	734	glue
O	735	736	(
O	736	743	Tisseel
O	743	744	)
O	745	746	(
O	746	747	n
O	748	749	=
B-intervention-participants	750	752	23
O	752	753	)
O	753	754	,
O	755	756	(
O	756	757	2
O	757	758	)
O	759	772	triamcinolone
O	773	782	acetonide
O	783	784	(
O	784	785	n
O	786	787	=
B-intervention-participants	788	790	26
O	790	791	)
O	791	792	,
O	793	795	or
O	796	797	(
O	797	798	3
O	798	799	)
B-control	800	806	normal
I-control	807	813	saline
I-control	814	815	(
I-control	815	822	control
I-control	822	823	)
O	824	825	(
O	825	826	n
O	827	828	=
B-control-participants	829	831	27
O	831	832	)
O	833	840	sprayed
O	841	845	into
O	846	849	the
O	850	855	donor
O	856	860	site
O	860	861	.

O	862	865	The
O	866	872	fourth
O	873	876	arm
O	877	885	included
O	886	891	donor
O	891	892	-
O	892	896	site
O	897	905	quilting
O	906	913	sutures
O	914	915	(
O	915	916	n
O	917	918	=
B-intervention-participants	919	921	20
O	921	922	)
O	922	923	.

O	924	932	Outcomes
O	933	941	included
B-outcome-Measure	942	948	seroma
O	948	949	,
B-outcome-Measure	950	955	drain
I-outcome-Measure	956	962	output
O	962	963	,
O	964	967	and
B-outcome-Measure	968	972	days
I-outcome-Measure	973	975	to
I-outcome-Measure	976	980	last
I-outcome-Measure	981	986	drain
I-outcome-Measure	987	994	removal
O	994	995	.

O	996	1001	Drain
O	1002	1009	removal
O	1010	1013	was
O	1014	1026	standardized
O	1027	1029	at
O	1030	1034	less
O	1035	1039	than
O	1040	1042	30
O	1043	1045	cc
O	1045	1046	/
O	1046	1049	day
O	1049	1050	.

O	1051	1054	All
O	1055	1061	groups
O	1062	1066	were
O	1067	1074	matched
O	1075	1081	evenly
O	1082	1089	without
O	1090	1101	differences
O	1102	1104	in
O	1105	1109	risk
O	1109	1110	,
O	1111	1121	procedures
O	1121	1122	,
O	1123	1125	or
O	1126	1139	complications
O	1139	1140	.

O	1141	1144	The
B-outcome	1145	1152	overall
I-outcome	1153	1159	seroma
I-outcome	1160	1164	rate
O	1165	1168	was
O	1169	1171	31
O	1171	1172	.
O	1172	1173	3
O	1174	1181	percent
O	1182	1183	(
O	1183	1184	n
O	1185	1186	=
O	1187	1189	30
O	1189	1190	)
O	1190	1191	.

O	1192	1195	The
O	1196	1204	quilting
O	1205	1210	group
O	1211	1214	had
O	1215	1228	significantly
O	1229	1233	less
B-outcome	1234	1242	drainage
I-outcome	1243	1246	for
I-outcome	1247	1252	weeks
I-outcome	1253	1254	1
O	1255	1256	(
O	1256	1257	p
O	1258	1259	=
O	1260	1261	0
O	1261	1262	.
O	1262	1265	006
O	1265	1266	)
O	1267	1270	and
O	1271	1272	2
O	1273	1274	(
O	1274	1275	p
O	1276	1277	=
O	1278	1279	0
O	1279	1280	.
O	1280	1283	050
O	1283	1284	)
O	1285	1300	postoperatively
O	1300	1301	.

O	1302	1310	Quilting
O	1311	1324	statistically
O	1325	1332	reduced
O	1333	1336	the
B-outcome	1337	1346	incidence
I-outcome	1347	1349	of
I-outcome	1350	1357	seromas
O	1358	1360	to
B-iv-bin-percent	1361	1362	5
I-iv-bin-percent	1362	1363	.
I-iv-bin-percent	1363	1364	0
I-iv-bin-percent	1365	1372	percent
O	1373	1374	(
O	1374	1375	n
O	1376	1377	=
B-iv-bin-abs	1378	1379	1
O	1379	1380	;
O	1381	1382	p
O	1383	1384	=
O	1385	1386	0
O	1386	1387	.
O	1387	1390	038
O	1390	1391	)
O	1392	1400	compared
O	1401	1405	with
O	1406	1411	other
O	1412	1418	groups
O	1419	1420	(
O	1420	1427	control
O	1427	1428	,
B-cv-bin-percent	1429	1431	34
I-cv-bin-percent	1431	1432	.
I-cv-bin-percent	1432	1433	5
I-cv-bin-percent	1434	1441	percent
O	1441	1442	;
O	1443	1449	fibrin
O	1449	1450	,
B-iv-bin-percent	1451	1453	27
I-iv-bin-percent	1453	1454	.
I-iv-bin-percent	1454	1455	6
I-iv-bin-percent	1456	1463	percent
O	1463	1464	;
O	1465	1468	and
O	1469	1482	triamcinolone
O	1482	1483	,
B-iv-bin-percent	1484	1486	37
I-iv-bin-percent	1486	1487	.
I-iv-bin-percent	1487	1488	6
I-iv-bin-percent	1489	1496	percent
O	1496	1497	)
O	1497	1498	.

B-outcome	1499	1505	Drains
I-outcome	1506	1510	were
I-outcome	1511	1518	removed
O	1519	1521	10
O	1522	1526	days
O	1527	1534	earlier
O	1535	1539	with
O	1540	1548	quilting
O	1549	1550	(
O	1550	1557	control
O	1557	1558	,
B-cv-cont-mean	1559	1561	35
I-cv-cont-mean	1561	1562	.
I-cv-cont-mean	1562	1563	5
I-cv-cont-mean	1564	1568	days
O	1568	1569	;
O	1570	1576	fibrin
O	1576	1577	,
B-iv-cont-mean	1578	1580	39
I-iv-cont-mean	1580	1581	.
I-iv-cont-mean	1581	1582	5
I-iv-cont-mean	1583	1587	days
O	1587	1588	;
O	1589	1602	triamcinolone
O	1602	1603	,
B-iv-cont-mean	1604	1606	37
I-iv-cont-mean	1606	1607	.
I-iv-cont-mean	1607	1608	4
I-iv-cont-mean	1609	1613	days
O	1613	1614	;
O	1615	1618	and
O	1619	1627	quilting
O	1627	1628	,
B-iv-cont-mean	1629	1631	25
I-iv-cont-mean	1631	1632	.
I-iv-cont-mean	1632	1633	8
I-iv-cont-mean	1634	1638	days
O	1638	1639	;
O	1640	1641	p
O	1642	1643	=
O	1644	1645	0
O	1645	1646	.
O	1646	1649	001
O	1649	1650	)
O	1650	1651	.

O	1652	1655	The
B-outcome	1656	1665	incidence
I-outcome	1666	1668	of
I-outcome	1669	1672	all
I-outcome	1673	1678	other
I-outcome	1679	1692	complications
O	1693	1696	was
O	1697	1704	similar
O	1705	1712	between
O	1713	1719	groups
O	1719	1720	.

O	1721	1724	The
O	1725	1728	use
O	1729	1731	of
O	1732	1740	quilting
O	1741	1746	donor
O	1747	1752	sites
O	1753	1766	significantly
O	1767	1776	decreases
O	1777	1780	the
O	1781	1790	incidence
O	1791	1793	of
O	1794	1799	donor
O	1799	1800	-
O	1800	1804	site
O	1805	1812	seromas
O	1813	1816	and
O	1817	1822	leads
O	1823	1825	to
O	1826	1833	earlier
O	1834	1839	drain
O	1840	1847	removal
O	1848	1857	following
O	1858	1868	latissimus
O	1869	1874	dorsi
O	1875	1879	flap
O	1880	1894	reconstruction
O	1895	1898	and
O	1899	1908	maintains
O	1909	1910	a
O	1911	1914	low
O	1915	1927	complication
O	1928	1935	profile
O	1935	1936	.

O	1937	1948	Therapeutic
O	1948	1949	,
O	1950	1952	II
O	1952	1953	.
